Oscar Health Inc. rose 6.69% in after-hours trading to $18.04 per share, reflecting optimistic market sentiment regarding the company's future, particularly in light of the ACA subsidy extension.
The U.S. House of Representatives passed a bill extending Affordable Care Act subsidies for three more years, which is expected to lower health insurance costs for millions of Americans, significantly improving Oscar Health's business outlook due to its heavy reliance on the ACA exchange market. Barclays upgraded Oscar's stock rating from 'Underweight' to 'Equal-Weight' and raised its price target from $13 to $18, further fueling the stock's rise and indicating strong market confidence in its future performance.
Oscar's stock has increased 16.71% year-to-date, showcasing strong performance in the overall market, with positive price trends in both short and long terms despite poor momentum rankings.
Wall Street analysts forecast OSCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR is 17.04 USD with a low forecast of 11.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast OSCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR is 17.04 USD with a low forecast of 11.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
2 Sell
Hold
Current: 14.870
Low
11.00
Averages
17.04
High
25.00
Current: 14.870
Low
11.00
Averages
17.04
High
25.00
UBS
Sell -> Neutral
upgrade
$12 -> $17
2026-01-09
Reason
UBS
Price Target
$12 -> $17
AI Analysis
2026-01-09
upgrade
Sell -> Neutral
Reason
UBS upgraded Oscar Health to Neutral from Sell with a price target of $17, up from $12. The firm believes that despite the expiration of the enhanced subsidies, Oscar's enrollment in the exchanges are holding up better than feared. UBS says the shares are fairly priced at this level.
Barclays
Andrew Mok
Underweight -> Equal Weight
upgrade
$13 -> $18
2026-01-05
Reason
Barclays
Andrew Mok
Price Target
$13 -> $18
2026-01-05
upgrade
Underweight -> Equal Weight
Reason
Barclays analyst Andrew Mok upgraded Oscar Health to Equal Weight from Underweight with a price target of $18, up from $13. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers." Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OSCR
Unlock Now
Jefferies
Jefferies
downgrade
$12
2025-12-22
Reason
Jefferies
Jefferies
Price Target
$12
2025-12-22
downgrade
Reason
Prospects for an Enhanced Advance Premium Tax Credit extension have diminished, with early Idaho open enrollment period enrollment up 3% year over year but offset by expected non-effectuation, higher voluntary disenrollment, and increased buy-down into bronze plans, Jefferies tells investors in a research note. In Georgia, Kaiser's pause on new enrollment heightens SEP-related medical loss ratio risk for Oscar Health, which is positioned with the first- and second-lowest-cost Silver plans in the state's four most populous counties, the firm says. Jefferies has an Underperform rating and $12 price target on Oscar Health shares.
Stephens
Stephens
Equal Weight
initiated
$17
2025-12-10
Reason
Stephens
Stephens
Price Target
$17
2025-12-10
initiated
Equal Weight
Reason
Stephens initiated coverage of Oscar Health with an Equal Weight rating and $17 price target. The firm believes the company's "pure-play focus" to the Affordable Care Act exchanges can be viewed as a "two-way street." The policies that drove Oscar towards profitability are also driving near-term uncertainty to its long-term growth trajectory, the analyst tells investors in a research note.
About OSCR
Oscar Health, Inc. is a healthcare technology company built around a full stack technology platform. The Company's offerings include its insurance business and +Oscar Platform. Its health plans are offered in the individual market. The individual market primarily consists of policies purchased by individuals and families through health insurance marketplaces, established by the ACA and operated by the federal government, as well as other marketplaces operated by individual states. Individuals and families may also purchase policies in the individual market off-exchange. Employees whose employers have chosen to offer an Individual Coverage Health Reimbursement Arrangement (ICHRA) are also able to purchase its health plans. It offers health plans in the individual market under the five metal plan categories defined by the ACA: Catastrophic, Bronze, Silver, Gold, and Platinum. Through the +Oscar platform, the Company deploys its technology to help others throughout the healthcare system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
